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Cost analysis was accepted at the Barcelona conference as a
special topic--this is the first time an international meeting has
included the subject. The two major areas where cost analysis is
urgently required in a medical laboratory which has an
increasing lack of funds are in the discussion of strategies for
selecting tests (which test, for example, has the highest
discriminative power for a special diagnostic problem?), and in
the choice of instruments (which instrument, or analytical
system, produces the least costs for special diagnostic
strategies?). Cost analysis is becoming more and more important
to decision-making in medical laboratories.
Although the need for cost analysis appears to be generMly
accepted, it is still undecided as to who should collect and
allocate costs and how this should be achieved. Comparison of
costs can only be useful if the processes of collection and
allocation are standardized and if definitions of terms used are
internationally accepted--the language applied must be under-
stood by all laboratory’ personnel.
The purpose ofthe symposium on cost analysis at Barcelona
was to provide a general summary of the present status of cost
analysis in the medical laboratory. Because ofa limit on time, the
reports presented could only introduce the field of costing. And
the symposium was intended to stimulate interest in costing
rather than to provide a detailed overview of the field.
The relation of the cost analysis symposium to automation
(the primary topic of the Barcelona Congress) was evident:
economical viewpoints are becoming more important, especially
in terms of expensive instrumentation and large, automated
multi-test systems which now influence the whole infrastructure
of a medical laboratory.
The papers read at the symposium follow.
Editor’s note: one symposium paper, received too late for
this issue, will be published in Journal ofAutomatic Chemistry,
Vol. 5, No. 3.
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The decision-making process surrounding the purchase ofnew
instruments in a medical laboratory involves several steps, and
many aspects have to be considered; this point was discussed
during the cost-analysis symposium organized by the IFCC’s
Expert Panel on Instrumentation in collaboration with the
IUPAC Commission on Automation and held at 1982’s
Barcelona meeting. The purpose of this paper is to discuss the
economic aspects of the process. Because large analytical
systems influence the whole organizational structure of the
laboratory, cost analysis and cost-benefit analysis must be
considered in respect of the total laboratory structure.
The primary task of the medical laboratory is to produce test
results--these usually lead to a number of effects:
Test
$ Expenditure
Result-- --,Efficiency
Effect(s)-- Effectiveness
The laboratory’s efficiency in fulfilling this task can be measured
by the quantity of results and by the costs incurred in obtaining
them (expenditure). The laboratory’s effectiveness is judged by
its ’utility’. (’Utility’ is a term commonly used in epidemiology
and in social economicsmsee references [1-8].)
Costs are usually considered in monetary units, whereas
utility can be monitored in monetary and in non-monetary
units. Before costs are discussed in detail a few aspects of utility
need to be considered.
Generally, an effective diagnostic strategy should lead to a
gain in utility. The expense must, in some way, serve the patient,
even if this is only a reduction in uncertainty [5]. The utility of
diagnostic and therapeutic steps can be a reduction of disease
course, a gain in life expectancy or prognostic hints. Utility can
be studied on a micro- or macroeconomic scale. In the first case,
utility is considered in a small unit (for example when buying a
new instrument); in the second, utility is looked at on a much
larger scale--its impact on a population for instance. If a
negative test result leads to an unjustified therapy being followed
or to an extension of a disease course, a loss of utility results.
’Net utility’ is the sum of all positive and negative utilities.
Cost-utility investigations have been divided into cost-
benefit and cost-effectiveness analyses [1-8] (see table 1).
In a cost-benefit analysis, expenses and utilities are con-
sidered in monetary units, these are finally summed so that the